<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049138</url>
  </required_header>
  <id_info>
    <org_study_id>M13-538</org_study_id>
    <secondary_id>2013-003530-33</secondary_id>
    <nct_id>NCT02049138</nct_id>
  </id_info>
  <brief_title>An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Rheumatoid Arthritis Subjects</brief_title>
  <official_title>A Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) With Upadacitinib (ABT-494)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, open-label extension study in RA subjects. The sub-study is
      to assess the impact of upadacitinib treatment (15 mg QD and 30 mg QD) with background MTX on
      immunological responses to Prevnar 13Â® in RA patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 24, 2014</start_date>
  <completion_date type="Anticipated">July 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 24, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Work Instability Scale - Rheumatoid Arthritis (RA-WIS)</measure>
    <time_frame>From Week 0 to Week 312</time_frame>
    <description>Using RA-WIS scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EQ-5D</measure>
    <time_frame>From Week 0 to Week 312</time_frame>
    <description>Using the EuroQol-5D scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR 70 Response Rate</measure>
    <time_frame>Up to Week 312</time_frame>
    <description>ACR criteria measures improvement in tender or swollen joint counts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Health Assessment Questionnaire Disability Index</measure>
    <time_frame>From Week 0 to Week 312</time_frame>
    <description>Determined by the Health Assessment Questionnaire (HAQ-DI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in High-Sensitivity C-Reactive Protein (hsCRP)</measure>
    <time_frame>From Week 0 to Week 312</time_frame>
    <description>Determined by hsCRP lab test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Patient's Global Assessment of Disease Activity</measure>
    <time_frame>From Week 0 to Week 312</time_frame>
    <description>Determined by VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in DAS28 [CRP]</measure>
    <time_frame>From Week 0 to Week 312</time_frame>
    <description>DAS28 [CRP] calculation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Patient's Assessment of Pain</measure>
    <time_frame>From Week 0 to Week 312</time_frame>
    <description>Determined by the Joint Evaluation, Visual Analog Scale (VAS), EuroQoL-5D (EQ-5D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Swollen Joint Count</measure>
    <time_frame>From Week 0 to Week 312</time_frame>
    <description>Swollen Joint Count will be assessed by a qualified Independent Joint Assessor or Principal Investigator using the Joint Evaluation Worksheet.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CDAI</measure>
    <time_frame>From Week 0 to Week 312</time_frame>
    <description>The sum of tender and swollen joint counts [28 joints] and patient and physician global assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR 50 Response Rate</measure>
    <time_frame>Up to Week 312</time_frame>
    <description>ACR criteria measures improvement in tender or swollen joint counts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects achieving Low Disease Activity</measure>
    <time_frame>Up to Week 312</time_frame>
    <description>Determined by disease activity score using 28 joint counts (DAS28) [CRP] or clinical disease activity index (CDAI) criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Scale</measure>
    <time_frame>From Week 0 to Week 312</time_frame>
    <description>Using the FACIT Fatigue Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>American College Rheumatology (ACR) 20 Response Rate</measure>
    <time_frame>Up to Week 312</time_frame>
    <description>ACR criteria measures improvement in tender or swollen joint counts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects achieving Clinical Remission</measure>
    <time_frame>Up to Week 312</time_frame>
    <description>Determined by DAS28 [CRP] and CDAI criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Tender Joint Count</measure>
    <time_frame>From Week 0 to Week 312</time_frame>
    <description>Tender Joint Count will be assessed by a qualified Independent Joint Assessor or Principal Investigator using the Joint Evaluation Worksheet.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Clinical Laboratory Data</measure>
    <time_frame>From Week 0 through 30 day follow-up visit (30 days after last dose of study drug)</time_frame>
    <description>Clinical Laboratory Data include hematology, clinical chemistry and urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with satisfactory humoral response to Prevnar 13</measure>
    <time_frame>Week 4 of the sub-study (approximately 136 weeks)</time_frame>
    <description>Satisfactory response is defined as greater than or equal to 2-fold increase in antibody concentration from the vaccination baseline in at least 6 out of the 12 pneumococcal antigens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with satisfactory humoral response to Prevnar 13</measure>
    <time_frame>Week 12 of the sub-study (approximately 252 weeks)</time_frame>
    <description>Satisfactory response is defined as greater than or equal to 2-fold increase in antibody concentration from the vaccination baseline in at least 6 out of the 12 pneumococcal antigens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in geometric mean fold rise of anti-pneumococcal antibody levels</measure>
    <time_frame>Up to Week 12 of the sub-study (approximately 252 weeks)</time_frame>
    <description>Anti-pneumococcal antibody levels to each of the 12 pneumococcal antigens above vaccination baseline values.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">494</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Open-label extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will start treatment with ABT-494.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-494</intervention_name>
    <description>Tablet; Oral</description>
    <arm_group_label>Open-label extension</arm_group_label>
    <other_name>Upadacitinib</other_name>
    <other_name>Rinvoq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who have completed Study M13-550 or Study M13-537 with Upadacitinib (ABT-494)
             and has not developed any discontinuation criteria.

          2. If the subject has evidence of new latent Tuberculosis (TB) infection, the subject
             must initiate and complete a minimum of 2 weeks (or per local guidelines, whichever is
             longer) of an ongoing TB prophylaxis before continuing to receive study drug.

          3. If female, subject must meet one of the following criteria:

               -  Postmenopausal (defined as no menses for at least 1 year).

               -  Surgically sterile (bilateral oophorectomy or hysterectomy).

               -  Practicing from the time of screening until at least 30 days after the last dose
                  of study drug at least TWO of the following methods of birth control:

                    1. Tubal ligation

                    2. Partner vasectomy (at least 6 months earlier) (the vasectomized male partner
                       should be the sole partner for that female subject)

                    3. Intrauterine device

                    4. A male condom with spermicidal jelly or cream

                    5. Diaphragm, contraceptive sponge or cervical cap with spermicidal jelly or
                       cream

                    6. Hormonal contraceptives (injected, oral, transdermal or implanted methods)
                       must have been taking at least 2 months prior to dosing

          4. Male subjects must agree to follow protocol-specified pregnancy avoidance measures,
             including refraining from donating sperm, for up to 30 days post last dose of study
             drug.

          5. Subjects must voluntarily sign and date an informed consent, approved by an
             Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the
             initiation of any screening or study specific procedures.

        Substudy:

          1. Must currently be enrolled in the main study.

          2. Must have been receiving a stable dose of upadacitinib (either 15 mg QD or 30 mg QD)
             for a minimum of 4 weeks prior to the Vaccination visit.

          3. Must have been on a stable dose of background methotrexate (no change in dose or
             frequency) for a minimum of 4 weeks prior to the Vaccination visit.

          4. If subject is on corticosteroids, must remain on a stable dose of â¤ 10 mg/day of
             prednisone or equivalent corticosteroid therapy for at least 4 weeks after the
             vaccination visit.

          5. Must meet the prescribing specifications as per local label requirements to receive
             Prevnar 13Â® vaccine.

          6. Willing to receive Prevnar13Â® vaccine.

        Exclusion Criteria:

          1. Pregnant or breastfeeding female.

          2. Ongoing infections at Week 0 that have NOT been successfully treated. Subjects with
             ongoing infections undergoing treatment may be enrolled BUT NOT dosed until the
             infection has been successfully treated.

          3. Anticipated requirement or receipt of any live vaccine during study participation
             including up to 30 days after the last dose of study drug.

          4. Laboratory values from the visit immediately prior to Baseline Visit (local
             requirements may apply) meeting the following criteria:

               -  Serum aspartate transaminase (AST) or alanine transaminase (ALT) &gt; 3.0 Ã Upper
                  Limit of Normal (ULN)

               -  Estimated glomerular filtration rate by simplified 4-variable Modification of
                  Diet in Renal Disease (MDRD) formula &lt; 40mL/min/1.73m2

               -  Total white blood cell count (WBC) &lt; 2,000/Î¼L

               -  Absolute neutrophil count (ANC) &lt; 1,000/Î¼L

               -  Platelet count &lt; 50,000/Î¼L

               -  Absolute lymphocytes count &lt; 500/Î¼L

               -  Hemoglobin &lt; 8 gm/dL

          5. Enrollment in another interventional clinical study while participating in this study.

          6. Consideration by the investigator, for any reason, that the subject is an unsuitable
             candidate to receive study drug.

        Substudy:

          1. Receiving any csDMARDs other than MTX

          2. Receiving &gt; 10 mg/day of prednisone or equivalent corticosteroid therapy.

          3. Receipt of any steroid injection within 4 weeks prior to Vaccination visit.

          4. History of severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar
             13Â®.

          5. History of any documented pneumococcal infection within the last 6 months prior to the
             vaccination visit.

          6. Receipt of any vaccine 4 weeks prior to the vaccination visit and/or anticipation of
             any vaccination for 4 weeks after the vaccination visit.

          7. Receipt of any pneumococcal vaccine.

          8. Subject is not suitable for the sub-study as per the Investigator's judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheum Assoc of North Alabama /ID# 135926</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis and Rheum Researc /ID# 135902</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032-9306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis &amp; Rheuma Research /ID# 135931</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.V. Mehta MD, Med Corporation /ID# 124092</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsd /Id# 128747</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances /ID# 135911</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orrin Troum, M.D. and Medical /ID# 135933</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robin K. Dore MD, Inc /ID# 135906</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Rheum Clin Trials Inc. /ID# 136716</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Valley Medical Group /ID# 135932</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>92395</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Clinic /ID# 135901</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Research Associates, LLC /ID# 124085</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606-1827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AARDS Research, Inc. /ID# 135910</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RASF - Clinical Research /ID# 124082</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants, LLC /ID# 124094</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713-2260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida /ID# 124087</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group, LLC /ID# 137774</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants /ID# 137398</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Research /ID# 135917</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center, Inc. /ID# 124090</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integral Rheumatology &amp; Immunology Specialists /ID# 140362</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources /ID# 128745</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Rheumatology Grp /ID# 128746</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Internal Medicine /ID# 135916</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRN Professional Research Network of Kansas, LLC /ID# 124091</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klein and Associates, MD., PA /ID# 124086</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology &amp; /ID# 124077</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Gr /ID# 124079</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>June DO, PC /ID# 124081</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group /ID# 124076</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis /ID# 135907</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Rheumatic Back Disorder /ID# 135913</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteo Assoc /ID# 132280</name>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <zip>88011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research, PLLC /ID# 131936</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210-8508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Rheumatic Disease Study Group, Inc. /ID# 135921</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242-4468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STAT Research, Inc. /ID# 134906</name>
      <address>
        <city>Vandalia</city>
        <state>Ohio</state>
        <zip>45377-9464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research Oklahoma /ID# 135904</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103-2400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Penn Rheumatology Assoc /ID# 135920</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Ctr Clinical Res /ID# 124089</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emkey Arthritis and Osteo Clin /ID# 135908</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 124080</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29486-7887</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ramesh Gupta /ID# 128744</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Rheum. Research /ID# 124083</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management /ID# 128751</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management /ID# 128752</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center /ID# 135905</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Institute for Clin Res /ID# 135912</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research /ID# 128753</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research /ID# 128754</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SW Rheumatology Res. LLC /ID# 135927</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain State Clinical Resear /ID# 124088</name>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <zip>26301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Rheumatology and Immunotherapy Center /ID# 135922</name>
      <address>
        <city>Franklin</city>
        <state>Wisconsin</state>
        <zip>53132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc /ID# 139348</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ReumaClinic Genk-Hasselt /ID# 137775</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Trimontsium /ID# 135328</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Kaspela /ID# 136212</name>
      <address>
        <city>Plovdiv</city>
        <zip>4001</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UHMAT Palmed Plovdiv /ID# 135355</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative Center /ID# 136736</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Sv. Ivan Rilski /ID# 135678</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Sv. Ivan Rilski /ID# 136210</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative Center /ID# 136209</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corp de Beneficencia Osorno /ID# 136189</name>
      <address>
        <city>Osorno</city>
        <zip>1710216</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quantum Research LTDA. /ID# 136188</name>
      <address>
        <city>Puerto Varas</city>
        <zip>5550170</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L.K.N. Arthrocentrum, s.r.o /ID# 128782</name>
      <address>
        <city>HluÄÃ­n</city>
        <state>Moravskoslezsky Kraj</state>
        <zip>748 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav Praha /ID# 137937</name>
      <address>
        <city>Prague 2</city>
        <state>Praha 2</state>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NuselskÃ¡ poliklinika, Revmatologie /ID# 137776</name>
      <address>
        <city>Prague 4</city>
        <state>Praha 4</state>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologie Bruntal, s.r.o /ID# 137782</name>
      <address>
        <city>BruntÃ¡l</city>
        <zip>79201</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artroscan s.r.o. /ID# 139347</name>
      <address>
        <city>Ostrava</city>
        <zip>722 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orszagos Reumatologiai es Fizi /ID# 128785</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Margit Szakrendelo /ID# 136676</name>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualiclinic Kft. /ID# 134170</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Allamvasutak Korhaz /ID# 139971</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veszprem Megyei Csolnoky Feren /ID# 128784</name>
      <address>
        <city>VeszprÃ©m</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center /ID# 140199</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center /ID# 139295</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD M+M Centers /ID# 132439</name>
      <address>
        <city>Adazi</city>
        <zip>2164</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arija's Ancane's Family Doctor /ID# 132437</name>
      <address>
        <city>Baldone</city>
        <zip>2125</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic ORTO /ID# 132438</name>
      <address>
        <city>Riga</city>
        <zip>1005</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinstile, S.A. de C.V. /ID# 137075</name>
      <address>
        <city>Cuauhtemoc</city>
        <state>Ciudad De Mexico</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigacion de las Enfermedades Reumatologicas SA de CV /ID# 137307</name>
      <address>
        <city>Mexico City</city>
        <zip>06090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliditer SA de CV /ID# 136876</name>
      <address>
        <city>Mexico City</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital /ID# 131908</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porter Rheumatology Ltd /ID# 133983</name>
      <address>
        <city>Nelson</city>
        <zip>7010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timaru Medical Specialists Ltd /ID# 131909</name>
      <address>
        <city>Timaru</city>
        <zip>7910</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Krakow /ID# 134749</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NBR Polska /ID# 136208</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>00-465</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne AMED /ID# 128835</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>01-518</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Warszawa /ID# 136650</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>01-869</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Internistyczno Reum. /ID# 135876</name>
      <address>
        <city>BiaÅystok</city>
        <state>Podlaskie</state>
        <zip>15-099</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Gdynia /ID# 137362</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <zip>81-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michal Bazela Higher-Med /ID# 138074</name>
      <address>
        <city>ElblÄg</city>
        <state>Warminsko-mazurskie</state>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>REUMED Filia nr 2 /ID# 128839</name>
      <address>
        <city>Lublin</city>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Lecznica MAK-MED s.c. /ID# 128838</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia Centrum Med /ID# 128840</name>
      <address>
        <city>Nowa SÃ³l</city>
        <zip>67-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicome sp. z o.o. /ID# 137397</name>
      <address>
        <city>Oswiecim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatna Praktyka Lekarska /ID# 128837</name>
      <address>
        <city>Poznan</city>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatika - Centrum Reumatologii NZOZ /ID# 140198</name>
      <address>
        <city>Warsaw</city>
        <zip>02-691</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reum-Medica S.C. /ID# 128841</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-244</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ramon L. Ortega-Colon, MD /ID# 128760</name>
      <address>
        <city>Carolina</city>
        <zip>00983</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group /ID# 128759</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mindful Medical Research /ID# 136211</name>
      <address>
        <city>San Juan</city>
        <zip>00918-3756</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University /ID# 136734</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tver Regional Clinical Hosp. /ID# 137576</name>
      <address>
        <city>Tver</city>
        <state>Tverskaya Oblast</state>
        <zip>170036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>II Dzhan Research Center /ID# 136652</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDMAN s.r.o. /ID# 136649</name>
      <address>
        <city>Martin</city>
        <zip>036 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinika Senica /ID# 134728</name>
      <address>
        <city>Senica</city>
        <zip>905 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panorama Medical Centre /ID# 138540</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winelands Medical Research Ctr /ID# 134669</name>
      <address>
        <city>Stellenbosch</city>
        <state>Western Cape</state>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Malaga /ID# 128847</name>
      <address>
        <city>MÃ¡laga</city>
        <state>Malaga</state>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comple Hosp Univ de A Coruna /ID# 128846</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital CIMA Sanitas /ID# 128849</name>
      <address>
        <city>Barcelona</city>
        <zip>08034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Univ de Elche /ID# 128851</name>
      <address>
        <city>Elche</city>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clin Univ San Carlos /ID# 128852</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Sofia /ID# 136653</name>
      <address>
        <city>San SebastiÃ¡n de Los Reyes</city>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Gaias /ID# 133868</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena /ID# 128853</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Luisa /ID# 135689</name>
      <address>
        <city>Sevilla</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Valm /ID# 134668</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiev Municipal Clin Hosp 3 /ID# 137334</name>
      <address>
        <city>Kiev</city>
        <zip>02125</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NSC-Strazhesko Ist Cardiology /ID# 137330</name>
      <address>
        <city>Kiev</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whipps Cross Univ Hospital /ID# 135683</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Suffolk Hospital /ID# 128858</name>
      <address>
        <city>Ipswich</city>
        <zip>IP33 2QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Allerton Hospital /ID# 141308</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warrington + Halton Hosp NHS /ID# 137514</name>
      <address>
        <city>Warrington</city>
        <zip>WA5 1LZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>Related Info.</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Musculoskeletal Disease</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Joint Diseases</keyword>
  <keyword>Anti-inflammatory Agents</keyword>
  <keyword>Antirheumatic agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

